Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Summit Therapeutics PLC (SMMT) Insider Trading Activity
Healthcare • Biotechnology • 105 employees
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Total Value
$78,999,927.10
Total Shares
3,480,173
Average Trade Value
$15,799,985.42
Most Active Insider
Duggan Robert W
Total Activity: $75,499,996
Largest Single Transaction
$75,499,996
by Duggan Robert W on Sep 11, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Sep 11, 2024 | 44,052 | $999,980 | 44,052 (+100.0%) | Grant | |
|
Chief Accounting Officer
Officer
|
Sep 11, 2024 | 22,026 | $499,990 | 131,426 (+16.8%) | Grant | |
|
COO and CFO
Director, Officer
|
Sep 11, 2024 | 44,052 | $999,980 | 3,020,242 (+1.5%) | Grant | |
|
Co-chief Executive Officer
Director, Officer
|
Sep 11, 2024 | 44,052 | $999,980 | 24,967,852 (+0.2%) | Grant | |
|
Co-chief Executive Officer
Director, Officer, 10% Owner
|
Sep 11, 2024 | 3,325,991 | $75,499,996 | 551,695,096 (+0.6%) | Grant |